TriPRIL CAR T-Cell Therapy Shrinks Myeloma Signs
A phase 1 trial at Mass General Brigham Cancer Institute reported results in patients with relapsed or refractory multiple myeloma.
Updated on Nov. 18, 2026 in Diseases

Investigators at the Mass General Brigham Cancer Institute reported in The Lancet that TriPRIL, an experimental CAR T-cell therapy, reduced or eliminated signs of cancer in 12 of 15 patients with relapsed or refractory multiple myeloma. Nine of the patients had previously seen their cancer progress after BCMA-directed CAR T-cell therapy.
Why it matters
Multiple myeloma often returns after existing treatments, and the trial suggests that targeting two proteins at once may help patients whose cancer has stopped responding to earlier CAR T-cell therapy. Larger and longer studies are needed before the approach can be considered for routine care.
The phase 1 trial enrolled 15 patients, and 12 responded with cancer signs falling by at least half. TriPRIL cells remained detectable in some patients' blood beyond six months, but the study's length and sample size leave its durability unresolved.
The players
Mass General Brigham Cancer Institute
A cancer research and treatment center affiliated with Mass General Brigham, one of the largest healthcare systems in the Boston area, where the TriPRIL phase 1 trial was conducted.
The Lancet
A long-established British peer-reviewed medical journal that published the findings of the TriPRIL trial.
The details
TriPRIL modifies a patient's T cells so they recognize two proteins on myeloma cells, BCMA and TACI. The trial reported no severe cases of cytokine release syndrome or neurotoxicity, and patients showed no immune reaction against the therapy.
Timeline
Nov 18, 2026: News-medical.net published a report on the TriPRIL study findings.
Health Landscape
The trial builds on BCMA-directed CAR T-cell therapy, which transformed treatment for relapsed myeloma but left some patients whose disease progressed on it. Adding TACI as a second target offers a possible route past that limitation, though it remains at an early stage.
For patients with relapsed multiple myeloma, TriPRIL is not yet a treatment option outside clinical trials. Anyone considering experimental cell therapy should discuss eligibility and trial enrollment with their oncology team.
The takeaway
Targeting two proteins on myeloma cells may help patients whose disease returned after earlier CAR T-cell therapy, though the approach still needs larger and longer studies. Patients interested in new options should ask their doctors about clinical trial opportunities.
What happens next
Researchers are planning a phase 2 trial with more patients and longer follow-up to determine how long the benefits last.
Further reading
Explore more on Cancer research and treatment advances in the Boston area.
More information
Read the full Lancet journal article on the TriPRIL trial01806-4/abstract) for complete study details.






